Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
Support MFO
Donate through PayPal
CVS Joins Express Scripts in Battle Over New Cholesterol Drugs
Something to look at if you are long healthcare, as the PBMs continue to become more aggressive in trying to push down prices of new drugs. (the article notes CVS, but is focused on Caremark, their PBM, which is the second largest.)
When there are a number of low cost alternatives to go to, having a high cost drug for this condition is going to be very sketchy for formularies everywhere. I don't see this one going very far right now.
Comments